Why past GLP-1 users stop, and what brings them back: side effects (35.3%) and cost (31.2%) lead, and the fix must match the reason, with 94.3% of cost quitters wanting coverage under $50 and 60.0% of side-effect quitters a lower dose
In October 2026, US past GLP-1 users most often said they stopped because of side effects (35.3%) or cost and lost coverage (31.2%, n=170), and the change that would bring them back matched the reason: 94.3% of cost quitters chose coverage under $50 a month and 60.0% of side-effect quitters a lower dose.
- Who was asked
- US past GLP-1 users, 170 clones, US
- When
- October 2026 (fielded 2 October 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question asks why people stop. We paired the reason with one forced choice of what would bring them back and one coverage-withdrawal scenario, so the reason and the remedy can be read together for each person.
Section 01: What the panel said
- #
35.3%
35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage
base 170
- #
94.3%
94.3% of those who stopped over cost or coverage (50 of 53) say insurance that brings the cost under $50 a month would most make them start again
base 53 · Stopped over cost or coverage
- #
60%
60.0% of those who stopped over side effects (36 of 60) want a lower dose with milder side effects, and only 6.7% (4 of 60) choose cheaper coverage
base 60 · Stopped over side effects · contrast
- #
48.2%
If coverage stopped partway through a restart, leaving about $500 a month, 48.2% would stop again, 41.2% would ask their doctor for a covered alternative and 5.3% would pay the full price
base 170 · caveat
35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage
02Why do past GLP-1 users stop taking the medication?
Two reasons account for two thirds of stopping. Side effects came first at 35.3% and the monthly cost or a loss of insurance coverage second at 31.2% (n=170). A further 19.4% stopped because they had reached their goal, 12.9% because the drug stopped working as well, and only 2 of 170 because of shortages or refill trouble. These are reasons the clones' source interviews state outright: in 50 of the 53 cost cases and 54 of the 60 side-effect cases the person had said so in their own words.
Stopping is not the end of the story. 51.8% say they have regained at least some of the weight since (n=170), and 18.2% most or all of it.
03Does one offer bring former users back?
The overall answer is coverage. 41.8% chose insurance that brings the cost under $50 a month as the one change that would most make them start again (n=170), against 28.2% for a lower dose with milder side effects and 14.1% for a once-daily pill. Only 6.5% said nothing would bring them back.
The interesting reading sits underneath that total. The lever a past user picks matches the reason they quit almost exactly. Of the 53 who stopped over cost, 94.3% chose coverage under $50. Of the 60 who stopped over side effects, 60.0% chose a lower dose and only 4 of 60 chose coverage. A cheaper price does very little for the largest group of quitters.
04What happens if coverage disappears partway through treatment?
We asked what a past user would do if they restarted and their insurer then stopped covering it, leaving around $500 a month to pay. 48.2% would stop again and 41.2% would ask their doctor for a covered alternative (n=170). Only 5.3% would pay the full price themselves, and the same 5.3% would move to a cheaper compounded or telehealth version.
The answer depends on why they quit the first time. 71.7% of the cost quitters would stop again (n=53), while 23 of the 33 who had stopped at their goal would ask their doctor to switch them. Coverage for these drugs is being withdrawn by some public and employer plans this fall, so this is not a hypothetical for everyone.
05What would a brand or access team do with this?
- Our reading: segment win-back by the reason for stopping before choosing the message. Cost quitters respond to a coverage or price route; side-effect quitters need a tolerability story, such as a slower titration or a lower maintenance dose.
- Our reading: a coverage withdrawal mostly moves patients to the prescriber, not to the cash market. A doctor-facing switching route to a covered alternative keeps more patients on treatment than a cash-pay offer would.
- Our reading: a pill is a modest lever on its own for people who have already stopped, at 14.1% (n=170), so format alone is unlikely to win them back.
Section 06: What they said, and the interview line it rests on
“Without a doubt, insurance coverage that brings the cost under $50 a month. The price was the only reason I stopped taking it in the first place. I had great results, experienced zero side effects, and really liked being on it. If I could get my insurance to cover it and make it truly affordable, I would be back on a GLP-1 in a heartbeat.”
Predicted from this line in the interview
“Yes. If I can find it more affordable, which I've been um actually looking for, or if I could get my insurance to cover it, then definitely I would I would be back on it in a heartbeat.”
“The main reason I stopped taking Mounjaro in the first place was the physical side effects. Dealing with the persistent nausea and stomach pain just got really old after six months, even though I did lose about 15 pounds. Don't get me wrong, paying around $200 a month was definitely steep and getting it down under $50 would be great, but the cost wasn't what pushed me to quit. If I'm going to start up again, the number one thing for me would be a lower dose with milder side effects so I don't feel sick all the time.”
Predicted from this line in the interview
“Just kind of like nauseous like my stomach hurt and like thing like things like that.”
“I would have to stop taking it again. Money was the only reason I stopped taking it in the first place, and right now things are tight with my husband losing his job and living on retirement. There's just no way I could pay $500 a month out of pocket. A small co-pay would be fine, but when it starts costing hundreds of dollars, I simply have to give it up.”
Predicted from this line in the interview
“living on retirement isn't it's not cutting it and uh so it's kind of hard right now.”
Section 07: How much should you trust this?
What we would defend
- The reasons for stopping are grounded in the interviews: in 50 of 53 cost cases and 54 of 60 side-effect cases the person's own quotes name that reason.
- The match between reason and lever is large and in both directions: 94.3% of cost quitters (n=53) chose coverage, and 4 of 60 side-effect quitters did.
- Two independent pulls of all 170 clones' answers agreed on every answer and equal the dashboard's counts.
What we would not
- The plateau group (22 of 170): only 11 of the 22 have an interview quote about the drug losing effect, so we report the group without reading into it.
- Any age or gender split: demographics are missing for 80 of the 170 clones.
- The cost option joins price and lost coverage, so the page cannot say how many stopped because a plan dropped them as opposed to the price.
- Restart intent as demand: 38.8% say they are likely to restart in the next 12 months (n=170) with no price or effort attached; we report it as direction only.
- The weight-regain shares as clinical outcomes: they are what past users report, not measured weights.
The main limitation
Every answer is a single forced choice predicted for each clone from interviews with the real person, so it shows which lever matters most to whom, not how many people a real offer would bring back.
Section 08: How was this run?
| Segment | Clones |
|---|---|
| Stopped: The monthly cost, or losing insurance coverage for it | 53 |
| Stopped: Side effects such as nausea, stomach problems or fatigue | 60 |
| Stopped: I reached my goal weight or health target | 33 |
| Stopped: It stopped working as well, or my weight loss plateaued | 22 |
| Stopped: Supply shortages or trouble getting refills | 2 |
Question wording as fielded
- What was the main reason you stopped taking your GLP-1 weight-loss or diabetes medication?
- Since you stopped taking your GLP-1 medication, what has happened to your weight?
- How likely are you to start taking a GLP-1 medication again in the next 12 months, on a scale of 1 to 5 where 1 is very unlikely and 5 is very likely?
- Which ONE of these would most make you willing to start taking a GLP-1 medication again?
- If you restarted a GLP-1 medication and your insurer stopped covering it partway through, leaving you to pay around $500 a month yourself, what would you most likely do?
What was not asked, and why
We did not ask about specific brands or price ladders (an earlier page covers restart at different prices), and we did not ask how long people took the medication. No brand list was given to the panel.
What changed from the obvious question
The obvious question asks why people stop. We paired the reason with one forced choice of what would bring them back and one coverage-withdrawal scenario, so the reason and the remedy can be read together for each person.
Fielded through Ask Brox on 2 October 2026.
More on GLP-1: starting, stopping and restarting · Pricing and price sensitivity · Pharma & HCP · GLP-1 Past Users (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
After stopping a GLP-1, 67.5% keep the weight off by changing their diet on their own and 17.5% by fitness; a $29 maintenance program would draw 62.0%, a $149 one 19.3%
67.5% 67.5% of past GLP-1 users rely most on eating less or eating differently on their own to keep the weight off, and 17.5% on exercise or a fitness routine. (base 166)
Read -
When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
65.5% 65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price. (base 139)
Read -
GLP-1 pill or injection? 37.5% of weekly injection users would switch at the same price, and a smaller weight loss cuts that to 17.0%
37.5% 37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to. (base 200)
Read -
GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month
70.8% 70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%). (base 137)
Read